Literature DB >> 21104044

Oral contraceptive use and bone.

Shuying Wei1, Tania Winzenberg, Laura L Laslett, Alison Venn, Graeme Jones.   

Abstract

Sex hormones play a key role in bone homeostasis, and oral contraceptive (OC) use may affect bone mass in women. However, the nature of the association between OC use and bone remains controversial. This paper critically reviews studies on OC use and bone published between January 2009 and August 2010. Studies of OC use and bone mass mainly focus on adolescents or young adults and showed mixed results. Weak evidence suggests that OC use has no effect or a beneficial effect on bone mass, except in women commencing OCs shortly after menarche, and a consistently negative effect on bone turnover markers. A limited number of studies have examined the effect of ultra-low-dose OC (20 μg ethinyl estradiol) on bone mass in adolescents or young adults, and present conflicting results. The lack of randomized trials indicates that further high-quality prospective studies are required to investigate the effect of OC use on bone mass, particularly the optimal dose and timing of initiation of OC use in adolescents requiring contraception.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21104044     DOI: 10.1007/s11914-010-0037-9

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  23 in total

1.  Effects of lifestyle and diet on bone health in young adult Chinese women living in Hong Kong and Beijing.

Authors:  Ruth Chan; Jean Woo; Winny Lau; Jason Leung; Ling Xu; Xihe Zhao; Wei Yu; Edith Lau; Nicholas Pocock
Journal:  Food Nutr Bull       Date:  2009-12       Impact factor: 2.069

Review 2.  Epidemiology of abnormal uterine bleeding.

Authors:  Manisha Palep-Singh; Andrew Prentice
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2007-10-23       Impact factor: 5.237

3.  Estrogen-progestin contraceptive use during adolescence prevents bone mass acquisition: a 4-year follow-up study.

Authors:  Essi Pikkarainen; Marjo Lehtonen-Veromaa; Timo Möttönen; Hannu Kautiainen; Jorma Viikari
Journal:  Contraception       Date:  2008-07-01       Impact factor: 3.375

4.  Oral contraception usage in relation to bone mineral density and bone turnover in adolescent girls.

Authors:  M Lattakova; M Borovsky; J Payer; Z Killinger
Journal:  Eur J Contracept Reprod Health Care       Date:  2009-06       Impact factor: 1.848

5.  Use of depot medroxyprogesterone acetate and fracture risk.

Authors:  Christian Meier; Yolanda B Brauchli; Susan S Jick; Marius E Kraenzlin; Christoph R Meier
Journal:  J Clin Endocrinol Metab       Date:  2010-08-04       Impact factor: 5.958

6.  Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.

Authors:  Maria W Greenwald; Oscar S Gluck; Eva Lang; Viatcheslav Rakov
Journal:  Menopause       Date:  2005-11-08       Impact factor: 2.953

Review 7.  The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation.

Authors:  P D Delmas; R Eastell; P Garnero; M J Seibel; J Stepan
Journal:  Osteoporos Int       Date:  2000       Impact factor: 4.507

8.  Detrimental effect of oral contraceptives on parameters of bone mass and geometry in a cohort of 248 young women.

Authors:  Manfred Hartard; Christine Kleinmond; Michael Wiseman; Ernst R Weissenbacher; Dieter Felsenberg; Reinhold G Erben
Journal:  Bone       Date:  2006-09-11       Impact factor: 4.398

9.  Oral contraceptive use and bone density in adolescent and young adult women.

Authors:  Delia Scholes; Laura Ichikawa; Andrea Z LaCroix; Leslie Spangler; Jeannette M Beasley; Susan Reed; Susan M Ott
Journal:  Contraception       Date:  2010-01       Impact factor: 3.375

10.  Bone mineral density in a cohort of adolescents during use of norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives and after discontinuation of norethisterone enanthate.

Authors:  Mags E Beksinska; Immo Kleinschmidt; Jenni A Smit; Timothy M M Farley
Journal:  Contraception       Date:  2009-01-17       Impact factor: 3.375

View more
  3 in total

Review 1.  Premenopausal Osteoporosis.

Authors:  Adi Cohen
Journal:  Endocrinol Metab Clin North Am       Date:  2016-11-24       Impact factor: 4.741

2.  Evaluation and management of the premenopausal woman with low BMD.

Authors:  Adi Cohen; Elizabeth Shane
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

3.  Reference intervals for serum osteocalcin concentrations in adult men and women from the study of health in Pomerania.

Authors:  Anke Hannemann; Nele Friedrich; Christin Spielhagen; Rainer Rettig; Till Ittermann; Matthias Nauck; Henri Wallaschofski
Journal:  BMC Endocr Disord       Date:  2013-03-13       Impact factor: 2.763

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.